BioLife Solutions Inc. (Nasdaq: BLFS) customer TiGenix reported positive Phase III ADMIRE-CD trial results for Cx601. Shares of BioLife gained 81 cents to $2.85.
BioLife Solutions customer reports positive data
August 31, 2015 at 14:03 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|